Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus salvage radiotherapy for PSA persistence or biochemical recurrence after radical prostatectomy
2021-001291-42Phase 2Active
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in recurrent prostate cancer (RPC) and prostate cancer (PCa), sponsored by Universitätsklinikum Freiburg. Primary endpoint: Complete biochemical response. Started Apr 2022; status: active.
02
Drugs
03
Conditions
recurrent prostate cancer (RPC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2021-001291-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001291-42.